Pitcairn’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,614
| Closed | -$5.05M | – | 318 |
|
|
2025
Q3 | $5.05M | Sell |
6,614
-1,346
| -17% | -$1M | 0.4% | 40 |
|
|
2025
Q2 | $6.21M | Sell |
7,960
-872
| -10% | -$678K | 0.41% | 43 |
|
|
2025
Q1 | $7.29M | Buy |
8,832
+144
| +2% | +$120K | 0.44% | 37 |
|
|
2024
Q4 | $6.71M | Sell |
8,688
-241
| -3% | -$200K | 0.4% | 41 |
|
|
2024
Q3 | $7.91M | Sell |
8,929
-621
| -7% | -$558K | 0.47% | 36 |
|
|
2024
Q2 | $8.65M | Buy |
9,550
+595
| +7% | +$476K | 0.53% | 33 |
|
|
2024
Q1 | $6.97M | Sell |
8,955
-310
| -3% | -$221K | 0.45% | 39 |
|
|
2023
Q4 | $5.4M | Sell |
9,265
-19
| -0.2% | -$11.1K | 0.4% | 41 |
|
|
2023
Q3 | $4.99M | Buy |
9,284
+1,686
| +22% | +$869K | 0.42% | 40 |
|
|
2023
Q2 | $3.56M | Sell |
7,598
-3
| -0% | -$1.26K | 0.3% | 48 |
|
|
2023
Q1 | $2.61M | Buy |
7,601
+480
| +7% | +$162K | 0.24% | 82 |
|
|
2022
Q4 | $2.61M | Sell |
7,121
-64
| -0.9% | -$22.7K | 0.26% | 78 |
|
|
2022
Q3 | $2.32M | Sell |
7,185
-928
| -11% | -$294K | 0.25% | 79 |
|
|
2022
Q2 | $2.63M | Buy |
8,113
+1,282
| +19% | +$385K | 0.28% | 69 |
|
|
2022
Q1 | $1.96M | Sell |
6,831
-434
| -6% | -$112K | 0.17% | 107 |
|
|
2021
Q4 | $2.01M | Buy |
7,265
+635
| +10% | +$161K | 0.13% | 115 |
|
|
2021
Q3 | $1.53M | Buy |
6,630
+451
| +7% | +$111K | 0.11% | 136 |
|
|
2021
Q2 | $1.42M | Sell |
6,179
-1,069
| -15% | -$215K | 0.1% | 148 |
|
|
2021
Q1 | $1.35M | Sell |
7,248
-2,512
| -26% | -$491K | 0.1% | 147 |
|
|
2020
Q4 | $1.65M | Sell |
9,760
-1,318
| -12% | -$197K | 0.13% | 112 |
|
|
2020
Q3 | $1.64M | Sell |
11,078
-961
| -8% | -$149K | 0.14% | 100 |
|
|
2020
Q2 | $1.98M | Buy |
12,039
+40
| +0.3% | +$6.14K | 0.19% | 80 |
|
|
2020
Q1 | $1.67M | Buy |
11,999
+6,977
| +139% | +$959K | 0.2% | 76 |
|
|
2019
Q4 | $661K | Sell |
5,022
-158
| -3% | -$18.3K | 0.06% | 204 |
|
|
2019
Q3 | $580K | Sell |
5,180
-4,855
| -48% | -$541K | 0.06% | 215 |
|
|
2019
Q2 | $1.11M | Sell |
10,035
-2,212
| -18% | -$260K | 0.11% | 117 |
|
|
2019
Q1 | $1.59M | Buy |
12,247
+1,453
| +13% | +$177K | 0.17% | 78 |
|
|
2018
Q4 | $1.25M | Buy |
10,794
+6,061
| +128% | +$677K | 0.14% | 93 |
|
|
2018
Q3 | $508K | Buy |
4,733
+690
| +17% | +$69K | 0.05% | 250 |
|
|
2018
Q2 | $345K | Sell |
4,043
-180
| -4% | -$14.8K | 0.04% | 352 |
|
|
2018
Q1 | $327K | Sell |
4,223
-542
| -11% | -$43.6K | 0.03% | 354 |
|
|
2017
Q4 | $403K | Buy |
4,765
+152
| +3% | +$12.9K | 0.04% | 303 |
|
|
2017
Q3 | $394K | Sell |
4,613
-156
| -3% | -$12.8K | 0.04% | 297 |
|
|
2017
Q2 | $393K | Sell |
4,769
-36
| -0.7% | -$2.94K | 0.05% | 286 |
|
|
2017
Q1 | $404K | Sell |
4,805
-10
| -0.2% | -$801 | 0.05% | 293 |
|
|
2016
Q4 | $354K | Buy |
4,815
+411
| +9% | +$30.6K | 0.04% | 339 |
|
|
2016
Q3 | $353K | Buy |
4,404
+113
| +3% | +$9.04K | 0.04% | 324 |
|
|
2016
Q2 | $337K | Buy |
4,291
+78
| +2% | +$5.87K | 0.04% | 314 |
|
|
2016
Q1 | $303K | Sell |
4,213
-179
| -4% | -$13.5K | 0.04% | 337 |
|
|
2015
Q4 | $370K | Sell |
4,392
-19,310
| -81% | -$1.6M | 0.04% | 293 |
|
|
2015
Q3 | $1.98M | Sell |
23,702
-6,103
| -20% | -$515K | 0.26% | 59 |
|
|
2015
Q2 | $2.49M | Buy |
29,805
+25,668
| +620% | +$1.96M | 0.29% | 64 |
|
|
2015
Q1 | $300K | Sell |
4,137
-83
| -2% | -$5.91K | 0.03% | 375 |
|
|
2014
Q4 | $291K | Buy |
4,220
+17
| +0.4% | +$1.15K | 0.03% | 372 |
|
|
2014
Q3 | $273K | Sell |
4,203
-52
| -1% | -$3.29K | 0.03% | 392 |
|
|
2014
Q2 | $265K | Sell |
4,255
-137
| -3% | -$8.17K | 0.03% | 390 |
|
|
2014
Q1 | $258K | Sell |
4,392
-548
| -11% | -$30.6K | 0.03% | 398 |
|
|
2013
Q4 | $252K | Sell |
4,940
-320
| -6% | -$16K | 0.03% | 414 |
|
|
2013
Q3 | $264K | Buy |
5,260
+186
| +4% | +$9.74K | 0.03% | 389 |
|
|
2013
Q2 | $249K | Buy |
+5,074
| New | +$276K | 0.03% | 381 |
|
Other funds holding LLY
Pitcairn's LLY Position: Q4 2025 in Review
Pitcairn sold out of Eli Lilly (LLY) in Q4 2025, closing a stake of 6,614 shares — an estimated $5.05M sold.
Pitcairn first reported a position in LLY in Q2 2013 and held it in 50 quarters. The position peaked at $8.65M in Q2 2024. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.
- Pitcairn reported no remaining Eli Lilly position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 6,614 Eli Lilly shares in Q4 2025, an estimated $5.05M.
- Pitcairn first reported a position in Eli Lilly in Q2 2013 and held it in 50 quarters.
- Pitcairn's Eli Lilly position peaked at $8.65M in Q2 2024.
- 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.